Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Decitabine in the treatment of myelodysplastic syndromes.

Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F.

Expert Rev Anticancer Ther. 2010 Jan;10(1):9-22. doi: 10.1586/era.09.164. Review.

PMID:
20014881
2.

Azacitidine for the treatment of myelodysplastic syndrome.

Cataldo VD, Cortes J, Quintás-Cardama A.

Expert Rev Anticancer Ther. 2009 Jul;9(7):875-84. doi: 10.1586/era.09.61. Review.

PMID:
19589026
3.

[Hypomethylating agents for the treatment of myelodysplastic syndromes].

Itzykson R, Fenaux P.

Bull Cancer. 2011 Aug;98(8):927-34. doi: 10.1684/bdc.2011.1411. Review. French.

4.

Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.

Joeckel TE, Lübbert M.

Semin Hematol. 2012 Oct;49(4):330-41. doi: 10.1053/j.seminhematol.2012.08.001. Review.

PMID:
23079063
5.

The euphoria of hypomethylating agents in MDS and AML: is it justified?

Sekeres MA.

Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15. Review.

PMID:
24309530
6.

In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.

Hackanson B, Robbel C, Wijermans P, Lübbert M.

Ann Hematol. 2005 Dec;84 Suppl 1:32-8. Review.

PMID:
16292549
7.

Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.

Xie M, Jiang Q, Xie Y.

Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):22-8. doi: 10.1016/j.clml.2014.04.010. Epub 2014 Jun 12. Review.

PMID:
25042977
8.

Digging deep into "dirty" drugs - modulation of the methylation machinery.

Pleyer L, Greil R.

Drug Metab Rev. 2015 May;47(2):252-79. doi: 10.3109/03602532.2014.995379. Epub 2015 Jan 8. Review.

9.

Therapy with azanucleosides for myelodysplastic syndromes.

Quintás-Cardama A, Santos FP, Garcia-Manero G.

Nat Rev Clin Oncol. 2010 Aug;7(8):433-44. doi: 10.1038/nrclinonc.2010.87. Epub 2010 Jun 15. Review.

PMID:
20551943
10.

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP.

Blood. 2007 Jan 1;109(1):52-7. Epub 2006 Aug 1.

11.

[Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].

Klepfish A, Silbershatz I, Lugassy G, Shimoni A, Mittelman M.

Harefuah. 2013 Oct;152(10):591-4, 624. Hebrew.

PMID:
24450031
12.

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.

Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP.

Cancer. 2007 Jan 15;109(2):265-73.

13.

[Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes].

Dvirnyk VN, Kokhno AV, Glasko EN, Gemdzhian ÉG, Diagileva OA, Platonova TL, Parovichnikova EN.

Ter Arkh. 2013;85(7):65-71. Russian.

PMID:
24137949
14.

Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.

Yun S, Vincelette ND, Abraham I, Robertson KD, Fernandez-Zapico ME, Patnaik MM.

Clin Epigenetics. 2016 Jun 14;8:68. doi: 10.1186/s13148-016-0233-2. eCollection 2016. Review.

15.

The role of azacitidine in the treatment of myelodysplastic syndromes.

Abdulhaq H, Rossetti JM.

Expert Opin Investig Drugs. 2007 Dec;16(12):1967-75. Review.

PMID:
18042004
16.

Pharmacokinetic evaluation of decitabine for the treatment of leukemia.

Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E.

Expert Opin Drug Metab Toxicol. 2011 May;7(5):661-72. doi: 10.1517/17425255.2011.575062. Review.

PMID:
21500965
17.

Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.

Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, Vij R, Abboud CN, Stockerl-Goldstein KE, Jacoby MA, Uy GL, Westervelt P, DiPersio JF.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1761-9. doi: 10.1016/j.bbmt.2015.05.026. Epub 2015 Jun 5.

18.

The role of decitabine in the treatment of myelodysplastic syndromes.

Atallah E, Kantarjian H, Garcia-Manero G.

Expert Opin Pharmacother. 2007 Jan;8(1):65-73. Review.

PMID:
17163808
19.

Demethylating agents in myeloid malignancies.

Garcia-Manero G.

Curr Opin Oncol. 2008 Nov;20(6):705-10. doi: 10.1097/CCO.0b013e328313699c. Review.

20.

Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.

Duong VH, Bhatnagar B, Zandberg DP, Vannorsdall EJ, Tidwell ML, Chen Q, Baer MR.

Leuk Lymphoma. 2015 Jun;56(6):1718-22. doi: 10.3109/10428194.2014.966708. Epub 2014 Nov 3.

PMID:
25263320

Supplemental Content

Support Center